The Health Ministry has notified the Medical Devices Rule, 2017 in which manufacturers of medical devices will be required to meet risk proportionate regulatory requirements.
The new rules framed in conformity with Global Harmonisation Task Force (GHTF) classifies medical devices based on associated risks, into Class A (low risk), Class B (low moderate risk), Class C (moderate high risk) and Class D (high risk), said a statement.
Masimo Unveils 2 Medical Devices for Patient Monitoring in India
Non-invasive patient monitoring devices help clinicians get the best results.
Advertisement
‘Manufacture of Class A and Class B medical devices will be licenced by State Licensing Authorities concerned after Quality Management System audit by an accredited Notified Body.’
Tweet it Now
"With a view to bring in the highest degree of professionalism in regulation of medical devices, a system of 'Third Party Conformity Assessment and Certification' through Notified Bodies is envisaged," said the statement.
According to the health ministry, the Notified Bodies will be accredited by the National Accreditation Board for Certification Bodies (NABCB).
Currently, only 15 categories of medical devices are regulated as drugs and to that extent, the current regulatory practices in India were not fully geared to meet the requirements of the medical devices sector in the country.
![Pryor Medical Devices’ New ER-REBOA Catheter Receives FDA Approval]( "Pryor Medical Devices’ New ER-REBOA Catheter Receives FDA Approval")
REBOA is a minimally invasive technique used by the trauma, critical care and emergency medicine community to temporarily occlude large vessels using a balloon.
The new rules seek to remove regulatory bottlenecks to make in India, facilitate ease of doing business while ensuring availability of better medical devices for patient care and safety.
"The manufacturer will, in such a case, be required to do self-certification of compliance with the requirements and based on such certification, the licence will be issued," the health ministry statement said.
"Manufacture of Class A and Class B medical devices will be licenced by State Licensing Authorities concerned after Quality Management System audit by an accredited Notified Body," said the statement, adding that for all manufacturing sites, Quality Management System will need to be aligned with ISO 13485.
"Manufacture of Class C and Class D medical devices will be regulated by the Central Licensing Authority and, where required, assistance of experts or notified bodies will be taken. Import of all medical devices will continue to be regulated by Central Drugs Standard Control Organization. A network of NABL accredited laboratories will be set up both, by the government and by other entities, for testing medical devices," said the ministry.
Conduct of clinical investigations will, while following the international practices, be conducted in a manner that ensures realisation of the twin objectives of patient safety and welfare and discovery of new medical devices.
Source: IANS
Currently, only 15 categories of medical devices are regulated as drugs and to that extent, the current regulatory practices in India were not fully geared to meet the requirements of the medical devices sector in the country.
Pryor Medical Devices’ New ER-REBOA Catheter Receives FDA Approval
REBOA is a minimally invasive technique used by the trauma, critical care and emergency medicine community to temporarily occlude large vessels using a balloon.
Advertisement
The new rules seek to remove regulatory bottlenecks to make in India, facilitate ease of doing business while ensuring availability of better medical devices for patient care and safety.
"The manufacturer will, in such a case, be required to do self-certification of compliance with the requirements and based on such certification, the licence will be issued," the health ministry statement said.
"Manufacture of Class A and Class B medical devices will be licenced by State Licensing Authorities concerned after Quality Management System audit by an accredited Notified Body," said the statement, adding that for all manufacturing sites, Quality Management System will need to be aligned with ISO 13485.
"Manufacture of Class C and Class D medical devices will be regulated by the Central Licensing Authority and, where required, assistance of experts or notified bodies will be taken. Import of all medical devices will continue to be regulated by Central Drugs Standard Control Organization. A network of NABL accredited laboratories will be set up both, by the government and by other entities, for testing medical devices," said the ministry.
Conduct of clinical investigations will, while following the international practices, be conducted in a manner that ensures realisation of the twin objectives of patient safety and welfare and discovery of new medical devices.
Source: IANS
Medtronic Medical Devices Firm to Provide Financial Assistance to Patients in the US
The company plans to offer high priced devices like stents, heart valves and pacemakers on monthly installments to low-income, underserved patients.
Advertisement
 India’s Leading Medical Devices Company Acquires UK-Based PenlonBPL Medical Technologies acquisition of Penlon will complement existing portfolio and will help in expanding its presence in critical care segment. | Advertisement
|
Advertisement
Latest Corporate News
The first World Health Organisation (WHO)/ International Labour Organisation (ILO) joint global monitoring report shows that more action is needed to ensure healthier, safer, more resilient, and more social workplaces.
Successful career transitions could be possible when people leverage their existing skills in the new occupation. A new Artificial Intelligence tool helps employees figure out the right job according to their current skill set.
AI and big data rule the pharmaceutical sector by enhancing the drug development process and increasing the marketing and sales of drugs
Insurance companies in the US are working towards adding food to their coverage menu to improve the people's health under their coverage and cut hospital costs.
Pharmaceutical companies need to make strategic decisions that will provide financial benefit while showing strong commitment to global health and their patients during the pandemic.